CME: Medical Management of Obesity in Women’s Health

GLP-1 Agonists: Are They Revolutionizing Obesity Treatment in Women’s Health?

GLP-1 Agonists: Are They Revolutionizing Obesity Treatment in Women’s Health?

Obesity can have serious effects on women, making weight loss key to improving health outcomes.

Available credits: 0.25

Time to complete: 15 Minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Obesity is a common and morbid disease that affects two-thirds of American women and can have serious adverse effects, including poor mental health outcomes, reduced quality of life/productivity, and increased mortality. Weight loss is key to improving health outcomes but achieving long-term weight goals are often hampered by the body’s compensatory metabolic mechanisms that return patients back to their original—or even higher—weight.

    To provide clinicians with the evidence-based strategies needed to facilitate appropriate diagnosis and management of obesity, this activity discusses the hormonal role of energy regulation in obesity, its metabolic adaptations, and how they collectively relate to an obese pathophysiology in women in addition to reviewing guideline-based management algorithms.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Andrea J. Singer, MD, FACP, CCD
    Director, Women's Primary Care
    Director, Bone Densitometry
    Department of Obstetrics and Gynecology
    MedStar Georgetown University Hospital
    Washington, DC

    Consulting Fees: AgNovos, Amgen, Eli Lilly, Radius, UCB
    Speaker Bureau: Amgen, Radius, TherapeuticsMD
    Contracted Research: Radius Health, UCB 

    Donna H. Ryan, MD
    Associate Executive Director, Clinical Research
    Pennington Biomedical Research Center
    Louisiana State University School of Medicine
    Baton Rouge, LA

    Consulting Fees: Alyvent, Amgen, Bausch Health, Boeringer Ingelheim, Epitomee, Gila Therapeutics, IFA Celtic, Janssen, KVK Tech, Novo Nordisk, Phenomix, Quintiles, Real Appeal (United Health), ReDesign Health, Sanofi, Scientific Intake
    Commercial Interest Speakers Burea: Novo Nordisk
    Contracted Research: SELECT Steering Committee (Novo Nordisk)
    Ownership Interest: Gila Therapeutics, Phenomix, Xeno Bioscience, Epitomee, ReDesign Health, Scientific Intake

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Stephen Chavez has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify women with obesity and determine their comorbidity risk, with a focus on T2DM and CVD
    • Describe the hormonal role in energy regulation and metabolic adaptations to the pathophysiology of obesity in women
    • Apply guideline-based algorithms to appropriately individualize treatment for women with obesity that is poorly managed with diet and exercise
    • Develop strategies to improve communication and engage patients in shared decision making during annual health visits
  • Target Audience

    This activity is designed to meet the educational needs of Ob/Gyns, primary care physicians, obesity specialists, other women’s health specialists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from Novo Nordisk.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments


We’re glad to see you’re enjoying Omnia Education…
but how about a more personalized experience?

Register for free